Table 4.
Detailed clinical characteristics of metastatic prostate cancer patients treated with androgen deprivation therapy.
| Clinical Parameter | Long PFS | Short PFS | p-Value |
|---|---|---|---|
| Number of patients | 15 | 15 | |
| PSA progression at last follow-up, n | 7/15 (47%) | 15/15 (100%) | |
| Age, median (quartiles) years | 67 (65–76) | 66 (61–80) | 0.678 * |
| PSA at baseline, median (quartiles) µg/L | 233 (91–330) | 144 (115–391) | 0.917 * |
| Gleason Score (Min-Max) | 7–10 | 7–10 | 0.466 # |
| Median time to PSA progression, (quartiles) months | 42 (25–49) | 14 (8.7–19) | <0.0001 * |
| Median time to death, (quartiles) months | 53 (42–71) | 41 (25–45) | 0.011 * |
| Docetaxel prior to PSA progression, n | 3 | 2 | 1.000 # |
| Treatment post PSA progression | |||
| Docetaxel, n | 2 | 3 | |
| Abiraterone, n | 2 | 2 | |
| Bicalutamide or Enzalutamide, n | 3 | 7 | |
| Radium-223, n | 1 | ||
| No treatment, n | 2 |
Abbreviations: PFS, PSA progression-free survival after androgen deprivation therapy; n, numbers. Data are divided according to median time to PSA progression, long PFS > 21 months and short PFS < 21 months. * p-value obtained using Mann–Whitney test. # p-value obtained using Fisher test.